Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Area of Science:

• Oncology
• Neuro-oncology
• Cancer Therapeutics

Background:

• Leptomeningeal metastases (LM) represent an advanced cancer stage with poor prognosis.
• Recent advances in cancer biology have led to novel targeted therapies, including small molecule inhibitors (SMIs) and immune checkpoint inhibitors (ICIs).
• The efficacy of these advanced therapies in the unique leptomeningeal space remains largely underexplored.

Purpose of the Study:

• To review the current understanding of novel therapeutic strategies for leptomeningeal metastases.
• To highlight the challenges in evaluating drug efficacy in the leptomeningeal compartment.
• To identify promising therapeutic avenues for patients with leptomeningeal disease.

Main Methods:

• Review of existing literature, including retrospective studies and prospective clinical trials.
• Analysis of the biological rationale for using SMIs and ICIs in leptomeningeal disease.
• Discussion of the blood-cerebrospinal fluid barrier and its implications for drug penetration.

Main Results:

• Several SMIs and ICIs have demonstrated preliminary activity in leptomeningeal metastases.
• Retrospective data and early trial results suggest potential efficacy for specific agents.
• Understanding drug penetration across the choroid plexus is crucial for interpreting treatment outcomes.

Conclusions:

• Despite challenges, emerging evidence supports the potential of SMIs and ICIs in treating leptomeningeal metastases.
• Further dedicated research and clinical trials are essential to optimize these therapies for LM patients.
• Targeted therapies offer a promising frontier for improving outcomes in this aggressive cancer stage.